ADRA2A
ENSG00000150594
Target class
GPCR
Chromosome
10
Approved drugs
34
Clinical candidates (approved and in development)
41
- Approved drugs
- 34
- Clinical candidates (approved and in development)
- 41
- Chemical probe available
- Yes
- Other names
- ADRAR
- Target name
- ADRA2A
- Gene name
- Adrenoceptor alpha 2A
- Gene symbol
- ADRA2A
- Protein name
- Alpha-2A adrenergic receptor (Alpha-2 adrenergic receptor subtype C10) (Alpha-2A adrenoreceptor) (Alpha-2A adrenoceptor) (Alpha-2AAR)
- ADRA2
- ADRA2R
- Gene biotype
- Protein coding
- Gene family
- Adrenoceptors
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 45
- Highest tissue expression
- 98.88
- Tissue specificity (Gini)
- 0.657
- Tissue specificity (tau)
- 0.873
- KEGG gene identifiers
- hsa:150
- Protein interaction confidence
- 0.822444
- Protein interaction partners
- 18
- R-HSA-390696
- R-HSA-392023
- R-HSA-400042
- R-HSA-418594
- R-HSA-418597
- R-HSA-5683826
- End position
- 111080907
- Start position
- 111077029
- Chromosome
- 10
- Strand
- Forward
- Cell membrane
- Multi-pass membrane protein .
- PubMed 23105096
- PubMed 35245122
- Tissue specificity (tau)
- 0.873307
- Expression inequality (Gini)
- 0.656585
Expression in transcripts per million
- Cervix - Ectocervix
- 98.88
- Adipose - Subcutaneous
- 91.91
- Cervix - Endocervix
- 84.33
- Breast - Mammary Tissue
- 56.22
- Adipose - Visceral (Omentum)
- 39.05
Expression in transcripts per million
- Cervix - Ectocervix98.88
- Adipose - Subcutaneous91.91
- Cervix - Endocervix84.33
- Breast - Mammary Tissue56.22
- Adipose - Visceral (Omentum)39.05
- Vagina37.74
- Ovary37.68
- Bladder25.71
- Nerve - Tibial23.32
- Pancreas18.56
- Thyroid18.37
- Skin - Sun Exposed (Lower leg)18.32
- Spleen13.58
- Uterus13.55
- Testis12.74
- Brain - Cerebellum12.22
- Prostate11.89
- Artery - Tibial11.74
- Skin - Not Sun Exposed (Suprapubic)10.58
- Brain - Cerebellar Hemisphere10.46
- Fallopian Tube10.16
- Minor Salivary Gland9.46
- Colon - Transverse9.08
- Artery - Coronary7.68
- Lung6.79
And 29 more, listed on the interactive page.
- GO:0001819
- GO:0007173
- GO:0007186
- GO:0007265
- GO:0007266
- GO:0008284
- GO:0010700
- GO:0030036
- GO:0030335
- GO:0032870
- GO:0042593
- GO:0043410
- GO:0045742
- GO:0045955
- GO:0046676
- GO:0050892
- GO:0050995
- GO:0051044
- GO:0051897
- GO:0061179
- GO:0071875
- GO:0071880
- GO:0071881
- GO:0071882
- GO:0090303
- GO:0005737
- GO:0005886
- GO:0016323
- GO:0043235
- GO:0004938
- GO:0005515
- GO:0019901
- GO:0031696
- GO:0031996
- GO:0032795
- GO:0042803
- GO:0051379
- GO:0051380
decreased body temperature
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased body temperature
- pancreas
- nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264memory impairment
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: memory impairment
- cardiovascular system
- nervous system
Evidence sourcedecreased blood pressure
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased blood pressure
- pancreas
- nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264Decreased, Decreased fecundity
Effects
- Inhibition/Decrease/Downregulation
Studies
- cell-based
Evidence sourceincreased convulsions
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased convulsions
- pancreas
- nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264hyperglycemia
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: hyperglycemia
- cardiovascular system
- nervous system
Evidence sourceanesthetic-sparing effect
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: anesthetic-sparing effect
- cardiovascular system
- nervous system
Evidence sourcesedation
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: sedation
- pancreas
- nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264weight gain
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: weight gain
- cardiovascular system
- nervous system
Evidence sourcedecreased gastric emptying
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased gastric emptying
- pancreas
- nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264decreased pain
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased pain
- pancreas
- nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264gastrointestinal prokinetic effects
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- clinical: gastrointestinal prokinetic effects
- cardiovascular system
- nervous system
Evidence sourcedecreased memory
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased memory
- pancreas
- nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264increased blood insulin
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased blood insulin
- pancreas
- nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264central hypotension (reduction of blood pressure and heart rate)
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: central hypotension (reduction of blood pressure and heart rate)
- cardiovascular system
- nervous system
Evidence sourcedecreased heart rate
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased heart rate
- pancreas
- nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264increased gastrointestinal transit
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased gastrointestinal transit
- pancreas
- nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264analgesia
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: analgesia
- cardiovascular system
- nervous system
Evidence sourceincreased pupil diameter
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased pupil diameter
- pancreas
- nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264hypothermia
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: hypothermia
- cardiovascular system
- nervous system
Evidence sourcedecreased blood insulin
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased blood insulin
- pancreas
- nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264sedation
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: sedation
- cardiovascular system
- nervous system
Evidence sourceincreased heart rate
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased heart rate
- pancreas
- nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264
decreased noradrenaline release and sympathetic neurotransmission
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: decreased noradrenaline release and sympathetic neurotransmission
- cardiovascular system
- central nervous system
PubMed 23197038increased gastrointestinal motility
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: increased gastrointestinal motility
- cardiovascular system
- central nervous system
PubMed 23197038increased insulin secretion
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: increased insulin secretion
- cardiovascular system
- central nervous system
PubMed 23197038decreased blood pressure
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: decreased blood pressure
- cardiovascular system
- central nervous system
PubMed 23197038mydriasis
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: mydriasis
- cardiovascular system
- central nervous system
PubMed 23197038sedation
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: sedation
- cardiovascular system
- central nervous system
PubMed 23197038decreased heart rate
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: decreased heart rate
- cardiovascular system
- central nervous system
PubMed 23197038receptor binding
Studies
- biochemical: NVS_GPCR_hAdra2A, is one of one assay component(s) measured or calculated from the NVS_GPCR_hAdra2A assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.
Biological samples
- cell-free
Evidence source
Related records
Trials (4,132)
- : Pulpal Blood Flow With the Use of Intra-nasal Anesthetic
- : Vascular Function in Health and Disease
- "Efficacy and Safety of Brimonidine Tartrate Preservative-Free Formulation in Adults With Ocular Redness"
- "Extended" (Alternate Day) Antipsychotic Dosing
- "Pecos" B-adrenergic and PPAR-G Stimulation Upregulates Lipid Metabolism in Human Subcutaneous Fat
- "The Effect Of Subcutaneous Epinephrine Dosage On Blood Loss In Surgical Incision"
- [11C]Yohimbine PET Study of alpha2-AR
- 0.01% and 0.025% Atropine Eye Drops Combined Auricular Acupoint Stimulation on Myopia Control and Corneal Endothelium Change
- 0.6 vs. 1.2 mg Atropine Together With Neostigmine 2.5 mg on Heart Rate in Patient Receiving Muscle Relaxant
- 1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain
- 10 Vs.15 mcg Norepinephrine Bolus in Severe Maternal Hypotension During Cesarean Delivery
- 15 mg Mirtazapine Orally Disintegrating Tablets, Fasting
- 15 mg Mirtazapine Orally Disintegrating Tablets, Non-Fasting
- 15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated
- 18F-DOPA PET to Elucidate the Antidepressant Mechanism of Lurasidone in Bipolar Disorder
- 24-hour IOP-lowering Effect of Brimonidine 0.1%
- 24-hr Intraocular Pressure Control With SIMBRINZA ®
- 28-30 Month Study Comparing Paliperidone Palmitate With Oral Risperidone for Treating Adults Diagnosed With Schizophrenia Within the Past 5 Years
- 4"S" - Seasonal Symptoms Suppression Study
- 4% Articaine and 2% Lidocaine by Intraligamentary Technique in Irreversible Pulpitis
Drugs (87)
- Alseroxylon Adrenergic receptor alpha antagonist
- Apomorphine
- Apraclonidine Adrenergic receptor alpha-2 agonist
- Apraclonidine hydrochloride Adrenergic receptor alpha-2 agonist
- Atipamezole
- Atropine
- Aviptadil Adrenergic receptor alpha antagonist
- Brimonidine Adrenergic receptor alpha-2 agonist
- Brimonidine tartrate Adrenergic receptor alpha-2 agonist
- Bromocriptine
- Cabergoline
- Celiprolol Adrenergic receptor alpha-2 antagonist
- Celiprolol hydrochloride Adrenergic receptor alpha-2 antagonist
- Chlorpromazine
- Clonidine Adrenergic receptor alpha-2 agonist
- Clonidine hydrochloride Adrenergic receptor alpha-2 agonist
- Detomidine
- Dexmedetomidine Adrenergic receptor alpha-2 agonist
- Dexmedetomidine hydrochloride Adrenergic receptor alpha-2 agonist
- Dipivefrin Adrenergic receptor agonist